Despite being preventable and treatable, scabies affects more than 130 million people worldwide at any given time, ...

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...

Sepsis-induced immunosuppression is now recognized as a major cause of septic death, and identifying effective strategies to counteract it poses a significant challenge. This immunosuppression results ...

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April ...

Even more dramatically, these mice were protected from sepsis, a potentially fatal ... existing treatments revolve around general immunosuppression or the blockade of single cytokines.

The core pathology of sepsis encompasses immune dysregulation, with studies in adults revealing that CCI patients frequently enter a prolonged immunosuppressive phase, marked by heightened ...

Incident sepsis-associated hospitalization was higher in men vs women, but excess risk was higher in women with certain chronic conditions and risk factors.

Inpatients with sepsis need targeted strategies to reduce frailty, which is a known risk factor for mortality in sepsis.